Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling.

Abstract excerpt

The development of cancer therapies may be improved by the discovery of tumor-specific molecular dependencies. The requisite tools include genetic and chemical perturbations, each with its strengths and limitations. Chemical perturbations can be readily applied to primary cancer samples at large scale, but mechanistic understanding of hits and further pharmaceutical development is often complicated by the fact...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Line, Tumor
• Share to Leukemia, Lymphocytic, Chronic, B-Cell